INBS

+ Watchlist + Portfolio

Intelligent Bio Solutions Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.67
52-Week Range: $1.52 – $24.90
Market Cap: $8.00M
P/E (TTM): —
EPS (TTM): -11.28
Dividend Yield: —

Advanced Metrics

Price/Book: 0.59
PEG Ratio: —
Return on Equity: -307.69%
Return on Assets: -76.20%
Gross Margin: 48.63%
Operating Margin: -345.98%
Profit Margin: -294.91%
Current Ratio: 1.44
Debt/Equity: 0.34
Total Debt: $1.82M
Free Cash Flow: $-7.06M
Revenue Growth: 35.80%
Earnings Growth: —
Enterprise Value: $5.63M

INBS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$1.26M	$3.11M	$3.05M
Cost of Revenue	$0.00	$930.20K	$1.69M	$1.81M
Gross Profit	$0.00	$326.67K	$1.43M	$1.25M
Research & Development	$3.85M	$507.42K	$1.67M	$2.40M
Selling, General & Admin	$4.92M	$8.03M	$9.26M	$8.88M
Operating Expenses	$8.34M	$8.76M	$11.71M	$11.67M
Operating Income	-$8.34M	-$8.44M	-$10.28M	-$10.42M
EBITDA	-$8.33M	-$9.47M	-$8.81M	-$9.33M
Pretax Income	-$8.33M	-$10.66M	-$10.19M	-$10.60M
Net Income	-$8.31M	-$10.63M	-$10.16M	-$10.57M
Diluted EPS	-1368.00	-1270.00	-63.80	-20.00
Diluted Shares	6110	8371	159274	527364

INBS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$8.24M	$1.54M	$6.30M	$1.02M
Receivables	$2.47M	$833.16K	$978.35K	$1.60M
Inventory	$0.00	$979.91K	$777.54K	$635.22K
Current Assets	$10.87M	$3.86M	$8.53M	$4.14M
Total Assets	$12.35M	$10.35M	$13.78M	$8.25M
Current Liabilities	$4.66M	$5.88M	$5.45M	$5.35M
Long-Term Debt	—	$402.86K	—	—
Total Debt	$0.00	$1.34M	$871.44K	$281.81K
Total Liabilities	$5.81M	$6.67M	$5.60M	$5.44M
Retained Earnings	-$31.18M	-$41.81M	-$51.96M	-$62.53M
Shareholders' Equity	$6.62M	$3.80M	$8.33M	$3.00M
Working Capital	$6.20M	-$2.02M	$3.08M	-$1.21M

INBS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$3.36M	-$7.38M	-$9.57M	-$9.68M
Capital Expenditure	-$380.22K	-$505.12K	-$221.43K	-$231.84K
Free Cash Flow	-$3.74M	-$7.88M	-$9.79M	-$9.91M
Depreciation & Amortisation	$0.00	$966.73K	$1.21M	$1.21M
Stock-Based Compensation	$0.00	$260.00K	$230.50K	$238.04K
Investing Cash Flow	-$880.22K	-$694.14K	-$221.43K	-$231.84K
Financing Cash Flow	$0.00	$1.44M	$14.56M	$4.60M
Net Change in Cash	-$4.24M	-$6.64M	$4.77M	-$5.31M

INBS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$728.87K	$843.88K	$1.11M	$896.77K	$1.06M
Cost of Revenue	$387.50K	$508.31K	$593.51K	$437.04K	$525.42K
Gross Profit	$341.37K	$335.58K	$518.29K	$459.74K	$535.38K
Research & Development	$358.35K	$582.47K	$486.17K	$522.11K	$893.98K
Selling, General & Admin	$2.41M	$2.72M	$2.66M	$2.34M	$2.46M
Operating Expenses	$2.90M	$3.22M	$3.26M	$3.07M	$3.48M
Operating Income	-$2.56M	-$2.88M	-$2.74M	-$2.61M	-$2.94M
EBITDA	-$2.24M	-$2.79M	-$2.69M	-$2.35M	-$2.58M
Pretax Income	-$2.55M	-$3.10M	-$2.99M	-$2.69M	-$2.87M
Net Income	-$2.54M	-$3.09M	-$2.98M	-$2.68M	-$2.86M
Diluted EPS	-4.41	—	-3.50	-2.82	-1.80
Diluted Shares	577191	—	854693	950829	1.59M

INBS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$2.81M	$1.02M	$1.66M	$740.37K	$6.86M
Receivables	$1.03M	$1.60M	$1.64M	$10.36M	$1.45M
Inventory	$683.49K	$635.22K	$628.18K	$590.25K	$597.47K
Current Assets	$5.11M	$4.14M	$4.48M	$12.17M	$9.75M
Total Assets	$9.58M	$8.25M	$10.04M	$17.65M	$14.86M
Current Liabilities	$4.56M	$5.35M	$5.06M	$5.13M	$4.61M
Total Debt	$511.18K	$281.81K	$1.95M	$1.92M	$1.85M
Total Liabilities	$4.64M	$5.44M	$6.61M	$6.76M	$6.11M
Retained Earnings	-$59.44M	-$62.53M	-$65.52M	-$68.19M	-$71.06M
Shareholders' Equity	$5.11M	$3.00M	$3.62M	$11.09M	$8.96M
Working Capital	$542.95K	-$1.21M	-$577.71K	$7.05M	$5.14M

INBS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$2.76M	-$2.21M	-$2.85M	-$1.57M	-$4.33M
Capital Expenditure	-$14.38K	-$208.52K	-$70.40K	-$68.23K	—
Free Cash Flow	-$2.77M	-$2.42M	-$2.92M	-$1.64M	-$4.32M
Depreciation & Amortisation	$296.83K	$306.17K	$303.38K	$281.90K	$290.39K
Stock-Based Compensation	$12.00K	$12.00K	$12.00K	$61.58K	$24.20K
Investing Cash Flow	-$14.38K	-$208.52K	-$70.40K	-$28.07K	$12.90K
Financing Cash Flow	$3.32M	$602.00K	$3.56M	$674.65K	$10.44M
Net Change in Cash	$551.84K	-$1.82M	$640.94K	-$920.94K	$6.12M

Market Snapshot

About

Intelligent Bio Solutions Inc. is a medical technology company developing rapid diagnostic testing devices and biosensor platforms. The company's flagship product is a non-invasive saliva-based rapid screening test system for detecting recent drug use, designed for workplace testing, criminal justice, and rehabilitation monitoring applications. INBS combines biosensor technology, microfluidics, and artificial intelligence to create portable diagnostic solutions that deliver lab-quality results at the point of care. The company aims to expand its platform to address multiple diagnostic markets beyond drug screening.